Tech Company Financing Transactions
Apollomics Funding Round
On 1/8/2019, Apollomics raised $100 million in Series B financing from OrbiMed.
Transaction Overview
Company Name
Announced On
1/8/2019
Transaction Type
Venture Equity
Amount
$100,000,000
Round
Series B
Investors
Proceeds Purpose
The new cash will fund, and likely add to, the more than 10 ongoing clinical trials for these combos, which will be helped by an R&D facility and manufacturing capabilities built in Hangzhou in the past year.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
989 East Hillsdale Blvd. 220
Foster City, CA 94404
USA
Foster City, CA 94404
USA
Phone
Website
Email Address
Overview
At Apollomics, we are a purpose driven company imagining a world without cancer. We let science drive our decision making to advance our programs. We believe in the power of partnerships to enhance our pipeline and broaden the patient populations we serve.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Guo-Liang Yu
Chief Financial Officer
Wilson Cheung
Chief Medical Officer
Fabio Benedetti
General Manager
Qian Shi
President
Sanjeev Redkar
Vice President
Scott Houston
VP - Manufacturing
Yuling Li
Browse more venture capital transactions:
Prev: 1/8/2019: Tidelift venture capital transaction
Next: 1/8/2019: Schrodinger venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs